Prevention of systemic infections caused by group B streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines.
Robbins
J B
JB
National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.
Schneerson
R
R
Vann
W F
WF
Bryla
D A
DA
Fattom
A
A
D016667:Bacterial Capsules / Q000276:immunology*; D002240:Carbohydrate Sequence; D005260:Female; D006801:Humans; D008969:Molecular Sequence Data; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control; D012409:Rubella / Q000517:prevention & control; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000276:immunology; D013290:Streptococcal Infections / Q000517:prevention & control*; D013292:Streptococcus agalactiae / Q000276:immunology; D018074:Vaccines, Conjugate / Q000627:therapeutic use*
D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate